Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"DNA damage response induction" refers to the activation of multiple cellular pathways upon the detection of DNA damage. The DNA damage response (DDR) encompasses the recognition of DNA lesions, activation of cell cycle checkpoints, recruitment of repair machinery (such as nucleotide excision repair, homologous recombination, nonhomologous end joining), and, if necessary, initiation of apoptosis to prevent propagation of damaged DNA. The DDR involves major protein families, including sensors (e.g., MRN complex), transducers (ATM, ATR kinases), and effectors (p53, Chk1/2, etc.). Targeting the DDR is a major focus in cancer therapeutics, but "DNA damage response induction" itself is not a specific molecule or target; rather, it denotes a functional process with many contributing molecular targets such as ATM, ATR, DNA-PKcs, p53, and others[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA damage response induction (DDR).